Eckert & Ziegler SE operates in the field of radiopharmaceuticals and medical technology, specializing in the development, manufacturing, and distribution of products and services that utilize radioactive isotopes. The company's offerings are primari…
Analysis
Middle-of-the-road
Eckert & Ziegler SE is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.
The price is expensive. You pay 26.0× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 10% yearly growth; analysts expect 12%. The price, in other words, assumes less than the experts do.
The trajectory is moderate and the balance sheet is sturdy. The company scores 18/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.
What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202383
63
2023202420252026
All-time high
100
Dec 2025
All-time low
63
Jun 2026
Average rank
93
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
35
34
42
17
Price/Earnings
51
15
25
14
Price/Book
31
13
36
10
Dividend Yield
67
44
23
32
Value (overall)
45
62
20
19
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.